Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 30

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 30
---
 2025 period was due to decreases in payroll and related expenses of approximately
$1,452,000, general and administrative expenses of $453,000 and professional fees of $315,000.

The $1,452,000 decrease in payroll and related
expenses was primarily due to an $826,000 charge in the prior period related to severance agreements and workforce reductions, a $516,000
decrease from lower headcount and related compensation, and a $108,000 reduction in stock-based compensation associated with the reduced
headcount. 

 20 

General and administrative expenses decreased
approximately $453,000 for the six months ended September 30, 2025, primarily due to the recognition of a $218,000 R&D tax incentive
for Australian R&D related to the trial, lower insurance costs of $66,000 from reduced headcount, and a $71,000 decrease in supplies.
Additional decreases of $14,000 in utilities, $8,000 in business-related taxes, $13,000 in computer software, and $28,000 across various
other categories contributed to the overall change. These decreases were partially offset by an approximate $33,000 rent charge for a
lost deposit.

Professional fees decreased approximately $315,000,
primarily due to lower investor relations of approximately $222,000, reduced general and SEC legal fees of approximately $119,000, and
a combined $72,000 decrease in scientific consulting, contract labor, and audit and accounting services, partially offset by $94,000 in
patent legal fees related to new filings, maintenance, and associated costs.

Net Loss

As a result of the changes in expenses noted above,
our comprehensive loss decreased from $5,375,443 in the six months ended September 30, 2024, to $3,258,202 in the six months ended September
30, 2025.

Basic and diluted loss attributable to common
stockholders was ($10.65) for the six months ended September 30, 2025, compared to ($40.15) for the six-month period ended September 30,
2024.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2025, we had a cash balance
of $5,853,493 and working capital of $4,848,883. This compares to a cash balance of $5,501,261 and working capital of $4,050,514 at March